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Epidemiology and etiology of childhood pneumonia
Igor Rudan,a Cynthia Boschi-Pinto,b Zrinka Biloglav,c Kim Mulholland d & Harry Campbell e
Abstract Childhood pneumonia is the leading single cause of mortality in children aged less than 5 years. The incidence in this age 
group is estimated to be 0.29 episodes per child-year in developing and 0.05 episodes per child-year in developed countries. This 
translates into about 156 million new episodes each year worldwide, of which 151 million episodes are in the developing world. Most 
cases occur in India (43 million), China (21 million) and Pakistan (10 million), with additional high numbers in Bangladesh, Indonesia 
and Nigeria (6 million each). Of all community cases, 7–13% are severe enough to be life-threatening and require hospitalization. 
Substantial evidence revealed that the leading risk factors contributing to pneumonia incidence are lack of exclusive breastfeeding, 
undernutrition, indoor air pollution, low birth weight, crowding and lack of measles immunization. Pneumonia is responsible for about 
19% of all deaths in children aged less than 5 years, of which more than 70% take place in sub-Saharan Africa and south-east Asia. 
Although based on limited available evidence, recent studies have identified Streptococcus pneumoniae, Haemophilus influenzae and 
respiratory syncytial virus as the main pathogens associated with childhood pneumonia.
Bulletin of the World Health Organization 2008;86:408–416.
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Introduction
In the early 1970s Cockburn & Assaad1 
generated one of the earliest estimates 
of the worldwide burden of communi-
cable diseases. In a subsequent review, 
Bulla & Hitze2 described the substantial 
burden of acute respiratory infections 
and, in the following decade, with data 
from 39 countries, Leowski3 estimated 
that acute respiratory infections caused 
4 million child deaths each year – 2.6 
million in infants (0–1 years) and 1.4 
million in children aged 1–4 years. In 
the 1990s, also making use of available 
international data, Garenne et al.4 fur-
ther refined these estimates by modelling 
the association between all-cause mortal-
ity in children aged less than 5 years and 
the proportion of deaths attributable 
to acute respiratory infection. Results 
revealed that between one-fifth and 
one-third of deaths in preschool children 
were due to or associated with acute 
respiratory infection. The 1993 World 
Development Report5 produced figures 
showing that acute respiratory infection 
caused 30% of all childhood deaths.
The increasing focus on the reduc-
tion of child mortality arising from 
the Millennium Declaration and from 
the Millennium Development Goal 
(MDG) 4 of “reducing by two-thirds, 
between 1990 and 2015, the under-five 
mortality rate”,6 has generated renewed 
interest in the development of more 
accurate assessments of the number 
of deaths in children aged less than 
5 years by cause. Moreover, the moni-
toring of the coverage of interventions 
to control these deaths has become 
crucial if MDG 4 is to be achieved; 
thus a more accurate establishment of 
the causes of deaths in children aged 
less than 5 years becomes crucial. In 
2001, WHO established the Child 
Health Epidemiology Reference Group 
(CHERG) – a group of independent 
technical experts, to systematically 
review and improve data collection, 
methods and assumptions underlying 
the estimates of the distribution of the 
main causes of death for the year 2000. 
In this paper, we summarize the findings 
of this group on the morbidity and mor-
tality burden of childhood pneumonia. 
We also provide new regional and coun-
try pneumonia morbidity estimates for 
the year 2000, and review the current 
understanding of the distribution of the 
main etiological agents of pneumonia 
among children aged less than 5 years.
Search strategy and 
selection criteria
Most of the morbidity and mortality 
estimates in this paper are based on 
work published by CHERG’s pneumo-
nia working group.7,8 As a first step, the 
group reviewed publications on child-
hood pneumonia and created a database 
including more than 2200 sources of 
information. Further details on the 
literature search strategies, inclusion 
criteria, methods and models used for 
estimating pneumonia burden were 
published elsewhere.7–9 However, the 
results of the distribution of global 
pneumonia episodes by regions and 
countries with the prevalence of expo-
sure to main risk factors have not yet 
been published. Thus, we present the 
details on methods and models used for 
estimating these disaggregated figures 
in Appendix A (available at: http://www.
who.int/bulletin/volumes/86/5/07-
048769/en/index.html).10–27
Incidence of clinical pneumonia
Rudan et al.8 calculated and published 
the first global estimate of the incidence 
of clinical pneumonia in children aged 
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less than 5 years for the year 2000. This 
estimate was based on the analysis of 
data from selected 28 community-based 
longitudinal studies done in developing 
countries that were published between 
1969 and 1999. These studies were the 
only sources meeting the predefined 
set of minimum-quality criteria for 
inclusion in the analysis.8 The estimated 
median incidence for developing coun-
tries was 0.28 episodes per child-year, 
with an interquartile range 0.21–0.71 
episodes per child-year.8 The variation 
in incidence between the selected studies 
was very large, most probably due to the 
distinct study designs and real differ-
ences in the prevalence of risk factors 
in the various study settings. Given the 
substantial uncertainty over the point 
estimate, we used a triangular approach 
to check for plausibility of our assessment 
of pneumonia incidence. The ranges 
obtained by the main appraisal and two 
ancillary assessments overlapped between 
the values of 148 and 161 million new 
episodes per year. Giving most weight 
to the estimate obtained through the 
main approach, the analyses suggested 
that the incidence of clinical pneumo-
nia in children aged less than 5 years in 
developing countries worldwide (WHO 
regions B, D and E; see Annex A) is 
close to 0.29 episodes per child-year. 
This equates to 151.8 million new cases 
every year, 13.1 million (interquartile 
range: 10.6–19.6 million) or 8.7% 
(7–13%) of which are severe enough to 
require hospitalization.8 In addition, a 
further 4 million cases occur in devel-
oped countries worldwide (all WHO 
regions A and Europe regions B and C). 
The regions and their populations are 
defined by WHO region and child and 
adult mortality stratum (Table 1 and the 
statistical annex of World Health Report 
2000, available: at http://www.who.int/
whr2001/2001/archives/2000/en/pdf/
Statistical_Annex.pdf ).22
It is of major public health interest 
to assess the distribution of these esti-
mated 156 million episodes by regions 
and countries to assist planning for pre-
ventive interventions and case manage-
ment at community and facility levels, 
including vaccine and antibiotic needs 
and delivery. Therefore, we calculated 
these figures with the model described 
in Appendix A. Table 2 shows the 15 
countries with the highest predicted 
number of new pneumonia episodes 
and their respective incidence. These 15 
countries account for 74% (115.3 mil-
lion episodes) of the estimated 156 mil-
lion global episodes. More than half of 
the world’s annual new pneumonia cases 
are concentrated in just five countries 
where 44% of the world’s children aged 
less than 5 years live: India (43 million), 
China (21 million) and Pakistan (10 
million) and in Bangladesh, Indonesia 
and Nigeria (6 million each). Differ-
ences in incidence of childhood clinical 
pneumonia in the world at the country 
level are shown in Fig. 1.
Country estimates of the number 
of clinical pneumonia cases among 
children aged less than 5 years were as-
sembled into six WHO regions (African 
Region, Region of the Americas, South-
East Asia Region, European Region, 
Eastern Mediterranean Region and 
Western Pacific Region) as well as into 
developing and developed regions. 
These aggregated results together with 
estimates of new episodes per child-year 
and the number of severe episodes are 
shown in Table 1. Estimates of clinical 
pneumonia incidence are highest in 
South-East Asia (0.36 episodes per 
child-year), closely followed by Africa 
(0.33 episodes per child-year) and by 
the Eastern Mediterranean (0.28 epi-
sodes per child-year), and lowest in the 
Western Pacific (0.22 episodes per child-
year), the Americas (0.10 episodes per 
child-year) and European Regions (0.06 
episodes per child-year).
We explored the plausibility of 
the model estimates by computing 
incidence for more extreme values of 
risk-factor prevalence. When prevalence 
of exposure was set to 1% (an idealized 
scenario roughly similar to that in the 
most developed countries of the world), 
the incidence computed by the model 
was less than 0.05 episodes per child-
year. This estimate is lower than those 
reported in two classic reports of clinical 
pneumonia incidence among children 
in the United States of America and in 
the United Kingdom in the 1970s and 
1980s, respectively, and is close to our 
current estimate for the year 2000 for 
the European Region.28,29 When the 
prevalence of exposure was set to 99% 
(an unrealistic scenario at the country 
level, even for the poorest countries 
of the world) the incidence computed 
by the model was about 0.77 episodes 
per child-year. This estimate is slightly 
above the upper limit of individually 
reported pneumonia incidence from 
the 28 community-based studies from 
the developing world (75% inter-
quartile range estimate of 0.71 episodes 
per child-year). The model yields plau-
sible estimates over a wide range of values 
of risk-factor prevalence, supporting its 
use for calculating the distribution of 
clinical pneumonia episodes.
Under-five mortality
Several attempts to understand world-
wide child pneumonia mortality have 
been made over the past 30 years.3–5,7,30 
Despite the difficulties of producing 
estimates with available evidence, pneu-
monia has consistently been estimated 
as the leading single cause of childhood 
mortality. Some of the complexities for 
developing these estimates include large 
differences in case definition of pneu-
monia between studies, low specificity 
Table 1.  Estimates of incidence and number of new cases per year of clinical 
pneumonia in children aged less than 5 years, by WHO regiona
WHO region Total population
aged 0–4 years
(millions)
Estimated 
incidence
(e/cy)
Estimated no. of  
new cases per year
(millions)
African 105.62 0.33 35.13
Americas 75.78 0.10 7.84
Eastern Mediterranean 69.77 0.28 19.67
European 51.96 0.06 3.03
South-East Asia 168.74 0.36 60.95
Western Pacific 133.05 0.22 29.07
Total (developing countries) 523.31 0.29 151.76
Total (developed countries) 81.61 0.05 4.08
Total 604.93 0.26 155.84
e/cy, episodes per child-year.
a  Up to 10% of all new cases may progress to severe episodes and require hospitalization.
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Table 2.  The 15 countries with the highest estimated absolute number of new cases 
of clinical pneumonia
Country Predicted no. of  
new cases (millions)
Estimated incidence
(e/cy)
India 43.0 0.37
China 21.1 0.22
Pakistan 9.8 0.41
Bangladesh 6.4 0.41
Nigeria 6.1 0.34
Indonesia 6.0 0.28
Ethiopia 3.9 0.35
Democratic Republic of the Congo 3.9 0.39
Viet Nam 2.9 0.35
Philippines 2.7 0.27
Sudan 2.0 0.48
Afghanistan 2.0 0.45
United Republic of Tanzania 1.9 0.33
Myanmar 1.8 0.43
Brazil 1.8 0.11
e/cy, episodes per child-year.
of verbal autopsies in community-based 
studies, the fact that similar symptoms 
from both pneumonia and malaria lead 
to death, difficulties in distinguishing 
pneumonia from sepsis in neonates and 
the synergy between several disorders 
leading to a single death.31
Two recent estimates of the total 
number of deaths due to clinical pneu-
monia have been made by CHERG. 
A single-cause model derived from 40 
studies published between 1961 and 
2000 and based on the relationship 
between the proportional mortality due 
to respiratory infections and the overall 
mortality in children aged less than 
5 years, estimated the number of deaths 
attributable to childhood pneumonia to 
be 1.9 million in 2000.7 However, the 
data sources used to model the relation-
ship between pneumonia proportional 
mortality and all-cause mortality were 
not representative of the whole world 
as most of the studies were from Latin 
America and only a few data points were 
from countries with very high all-cause 
mortality. Moreover, many of them had 
been done more than three decades 
ago, in the 1960s and 1970s. A multiple-
cause model that analysed 38 more 
recent studies (average midstudy surveil-
lance year of 1990) from sub-Saharan 
Africa and south Asia, in countries with 
mortality rates for children aged less 
than 5 years of at least 26 per 1000 live 
births, predicted a similar number of 
deaths attributable to pneumonia (i.e. 
approximately 1.8 million under-5 
pneumonia deaths in these two regions 
in the year 2000).32
Some evidence suggests, how-
ever, that both models underestimate 
the number of deaths attributable to 
clinical pneumonia in children aged less 
than 5 years. Many neonatal deaths 
have been attributed to severe infec-
tions33 that have not been taken into 
account in these models (Fig. 2). The 
exact proportion of pneumonia among 
these infections has not been clearly 
established because of the difficulties 
in distinguishing causes among severe 
infections in newborns. However, at 
least another 300 000 deaths caused 
by pneumonia are likely to occur 
worldwide during the neonatal period 
(Lawn J, personal communication).
The interquartile range for available 
case-fatality ratios was 1.3–2.6%, lead-
ing to an estimated 1.96–3.92 million 
expected deaths from pneumonia per 
year based on the basis of observed inci-
dence.8 Therefore, two lines of evidence 
both indicate that there are more than 
2 million deaths due to pneumonia each 
year in children aged less than 5 years.
The relative importance of the dif-
ferent causes of death in children aged 
less than 5 years varies across regions of 
the world, although the major causes, 
such as pneumonia, remain the same 
(Fig. 2). As with the incidence of pneu-
monia, mortality is unequally distrib-
uted.6 The proportion of pneumonia-
attributed deaths varies widely between 
WHO regions and significantly in-
creases in relative importance in regions 
that have inefficient health systems 
(Fig. 2).
The African Region has, in general, 
the highest burden of global child mor-
tality (Fig. 2). Although it comprises 
about 20% of the world’s population 
of children aged less than 5 years,22 
it has about 45% of global under-5 
deaths and 50% of worldwide deaths 
from pneumonia in this age group.34 By 
contrast, less than 2% of these deaths 
take place in the European Region 
and less than 3% in the Region of the 
Americas. More than 90% of all deaths 
due to pneumonia in children aged less 
than 5 years take place in 40 countries. 
Even more striking is the fact that, ac-
cording to the official estimates from 
WHO for the year 2000, two-thirds 
of all these deaths are concentrated in 
just 10 countries 34: India (408 000 
deaths), Nigeria (204 000), the Demo-
cratic Republic of the Congo (126 000), 
Ethiopia (112 000), Pakistan (91 000), 
Afghanistan (87 000), China (74 000), 
Bangladesh (50 000), Angola (47 000) 
and Niger (46 000; Table 3).
Although the absolute number of 
deaths provides important information 
regarding the global magnitude of the 
problem, it does not take into account 
the size of the population at risk and 
hence does not reflect the risk of death. 
For instance, while China has the sev-
enth highest absolute number of pneu-
monia deaths in children aged less than 
5 years, the mortality is about 8.6 per 
10 000, whereas several countries have 
rates above 100 per 10 000.
Beyond inter-country inequities, 
further critical inequities are present 
within countries, where children from 
the poorest families, living in rural 
areas and whose mothers are less edu-
cated, are those more likely to die from 
pneumonia. Data on the distribution of 
causes of death within countries from 
the demographic and health surveys 
done in Bangladesh in 2004 show dif-
ferentials in mortality due to acute 
respiratory infections by divisions, place 
of residence (rural/urban) and mother’s 
education. Deaths due to acute respira-
tory infections were proportionately 
more common in the Sylhet division 
and least common in Rajshahi, with a 
1.4-fold difference between the two. 
These infections were also a more com-
mon cause of death in rural (22.3%) 
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Fig. 1. Incidence of childhood clinical pneumonia at the country level
  0.10
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0.41–0.50
Episodes per child-year
than in urban (16.8%) areas. Further-
more, acute respiratory infection was 
associated with a large proportion of 
deaths among children of mothers with 
no education.35
Causes of pneumonia in children
Childhood clinical pneumonia is caused 
by a combination of exposure to risk 
factors related to the host, the environ-
ment and infection. To identify the 
former two categories of causal factors 
for development of pneumonia at the 
community level, we used the methods 
described in steps 2–4 of Appendix A. 
We then established the following cat-
egories of risk factors for childhood 
pneumonia: definite (most evidence 
consistently pointing to the role of the 
risk factor); likely (most evidence con-
sistently pointing to the role, but with 
some opposing findings; or scarce but 
consistent evidence of the role); and 
possible (with sporadic and inconsistent 
reports of the role in some contexts). 
These risk factors for development of 
pneumonia, related to the host or the 
environment, are listed in Box 1. In 
the remainder of this paper, we discuss 
etiological agents associated with child-
hood pneumonia.
Before vaccines were available, the 
cause of childhood pneumonia was 
a matter of great interest as specific 
therapy was available for pneumococcal 
pneumonia of certain serotypes, requir-
ing not only an etiological diagnosis 
for effective therapy, but also pneumo-
coccal serotyping. Studies from that 
era identified Streptococcus pneumoniae 
(pneumococcus) and Haemophilus in-
fluenzae as the main bacterial causes 
of pneumonia, with some severe cases 
caused by Staphylococcus aureus and 
Klebsiella pneumoniae.36 In the modern 
era, our understanding of the causes of 
pneumonia in developing countries is 
based on two types of study. The first 
type consists of prospective hospital-
based studies that have relied on blood 
cultures and, in some studies, of percu-
taneous lung aspiration.37 Some other 
studies also examined nasopharyngeal 
specimens for virus identification.38 
This approach lacks sensitivity for 
the identification of bacterial cause. 
Attempts to augment culture-based 
methods with various indirect markers 
of bacterial cause have been largely 
unsuccessful as the tests employed have 
been unable to distinguish between 
carriage of pneumococcus and H. in-
fluenzae, which is usual for children 
in developing countries, and invasive 
disease.39 The second type of study is 
the vaccine trial, in which the burden 
of pneumonia prevented by a specific 
vaccine is presumed to be a minimum 
estimate of the burden of pneumonia 
due to the organism against which the 
vaccine is directed.40
In prospective, microbiology-based 
studies, the leading bacterial cause is 
pneumococcus, being identified in 
30–50% of pneumonia cases.36,37,41–45 
The second most common organism 
isolated in most studies is H. influenzae 
type b (Hib; 10–30% of cases), fol-
lowed by S. aureus and K. pneumoniae. 
In addition, lung aspirate studies have 
identified a significant fraction of acute 
pneumonia cases to be due to Myco-
bacterium tuberculosis, which is notori-
ously difficult to identify in children.45 
Controversy surrounds the role of three 
important organisms, non-typable H. 
influenzae (NTHI), S. aureus and non-
typhoid Salmonella spp. NTHI was 
found to be an important pathogen in 
a lung aspirate study from Papua New 
Guinea,43 whereas in a series of lung 
aspirate studies from the Gambia, and 
in most blood culture-based studies, 
Hib was the main type of H. influenzae 
identified.37 Studies from Pakistan 
found NTHI to be a common blood 
culture isolate,46,47 but this has not 
been replicated elsewhere. The first ma-
jor study of the modern era that used 
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Fig. 2. Distribution of deaths from pneumonia and other causes in children aged less than 5 years, by WHO region
AFR, African Region; AMR, Americas Region; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region.
lung aspiration on over 500 children 
in Chile, including normal controls, 
found S. aureus to be the main patho-
gen.48 This finding has not been repli-
cated in more recent studies, although 
a recently completed WHO study of 
very severe (hypoxaemic) pneumonia 
in seven countries found S. aureus in 
47 of the 112 cases (42% of cases) in 
which a bacterium was identified, mak-
ing it the second largest cause.49 The role 
of non-typhoid Salmonella spp. is also 
unclear. Studies from Africa have shown 
bacteraemia caused by non-typhoid 
Salmonella spp. to be common50,51 and 
often associated with malaria. Although 
the work of Graham et al.52 in Malawi 
has implicated non-typhoid Salmonella 
spp. in radiological pneumonia cases, the 
role of these organisms in pneumonia 
is still unclear, as blood-culture studies 
have focused on children with fever 
and fast breathing and, therefore, may 
have identified children with bacterae-
mia only.53
The two causes of bacterial pneu-
monia that are vaccine-preventable are 
Hib and pneumococcus.54–60 In both 
cases, the vaccines will prevent most 
pneumonia due to each pathogen, and 
microbiological methods will detect 
only a few cases. Thus, the vaccine 
probe concept has emerged to describe 
studies that are designed to determine 
the burden of pneumonia that can be 
prevented by the vaccine, and is there-
fore attributable to the organism. These 
studies have used the WHO definition 
of radiological pneumonia as the main 
outcome. For Hib, two randomized 
controlled trials,54,55 one open trial,56 
a case–control study with random al-
location of vaccine57 and several other 
case–control studies have led to the con-
clusion that, in developing countries 
with a high burden of pneumonia, 
15–30% of radiological pneumonia 
cases, and probably the same proportion 
of pneumonia deaths, are due to Hib. 
For pneumococcus, three randomized 
controlled trials in developing countries 
have shown that the nine-valent pneu-
mococcal conjugate vaccine can prevent 
20–35% of radiological pneumonia 
cases and probably a similar proportion 
of pneumonia deaths.58–60 The newer 
pneumococcal vaccines covering 10–13 
serotypes will likely extend this protec-
tion considerably. In addition, one of 
the vaccines contains elements that 
may prevent non-typable H. influenzae 
pneumonia as well. Thus, future pneu-
mococcal vaccines may prevent 30–50% 
of radiological and fatal pneumonia. 
WHO has recently established modelled 
estimates of the number of pneumonia 
cases and deaths that are attributable 
to these organisms on a country-by-
country basis. These estimates will be 
available soon (Kate O’Brien, Thomas 
Cherian and Maria D Knoll, personal 
communications).
Pneumonia etiology studies that 
incorporate viral studies show that 
respiratory syncytial virus is the leading 
viral cause, being identified in 15–40% 
of pneumonia or bronchiolitis cases 
admitted to hospital in children in de-
veloping countries, followed by influ-
enza A and B, parainfluenza, human 
metapneumovirus and adenovirus.38,61,62 
In the prospective microbiology-based 
studies, viral causes of pneumonia are 
identified by rapid diagnostic tests 
(such as indirect immunofluorescence, 
enzyme-linked immunosorbent assay, 
polymerase chain reaction, viral culture 
on upper respiratory secretions – such 
as in nasopharyngeal aspirates – or by 
viral serology in paired samples).38,61 It 
will be some time before any of these 
causes are preventable by routine im-
munization.
Weber et al.38 made the most infor-
mative overview of respiratory syncytial 
virus. Because this virus is fragile, it is 
difficult to detect and its importance is 
probably underestimated. It was found 
in substantial frequency in all climatic 
and geographical areas, with sharp 
peaks of activity over a period of 2–4 
months, but its seasonality varies con-
siderably between regions. The peaks 
typically occur in the cold season in tem-
perate climates and in the rainy season 
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Table 3.  The 15 countries with the highest estimated number of deaths due to clinical 
pneumonia
Country Predicted no. of  
deaths (thousands)
Estimated mortality rates
(per 10 000 under-five 
population)
India 408 32.2
Nigeria 204 84.7
Democratic Republic of the Congo 126 110.1
Ethiopia 112 84.6
Pakistan 91 48.1
Afghanistan 87 185.9
China 74 8.6
Bangladesh 50 26.6
Angola 47 157.1
Niger 46 173.9
Uganda 38 67.6
United Republic of Tanzania 36 52.6
Mali 32 147.8
Kenya 30 50.3
Burkina Faso 25 99.4
in tropical climates. Disease burden esti-
mates from vaccine-probe studies are not 
yet available as for Hib and pneumococ-
cus, but such data may become available 
from monoclonal antibody trials, which 
show high efficacy against severe disease 
caused by respiratory syncytial virus. Pri-
mary respiratory infection by this virus 
increases the risk of secondary bacterial 
pneumonia and viral or bacterial coin-
fection is a common finding in young 
children with pneumonia in developing 
countries (approximately 20–30% of 
episodes).41,46 Furthermore, episodes 
of wheezing due to reactive airways are 
more common after such episodes. Some 
two-thirds of the episodes are seen in 
the first year of life, with 1.5–1.8 times 
greater frequency in boys than in girls. 
This implies that any vaccination efforts 
would need to be made early in life. The 
risk of pneumonia or bronchiolitis caused 
by respiratory syncytial virus is highest 
among children aged less than 2 years 
with the most severe disease occurring in 
infants aged 3 weeks to 3 months.63,64 A 
recent postmortem study of lung tissue 
samples from 98 Mexican children aged 
less than 2 years who died of pneumonia, 
which used nested polymerase chain 
reactions, showed that 30% were posi-
tive for respiratory syncytial virus: 62% 
of those with histopathological diagnosis 
of viral pneumonia and 25% with di-
agnosis of bacterial pneumonia.65 This 
study reaffirmed the role of respiratory 
syncytial virus as a very significant and 
potentially deadly pathogen that causes 
childhood pneumonia, both alone and 
through mixed infections with bacterial 
causes.
In recent years, the HIV epidemic 
has also contributed substantially to 
increases in incidence and mortal-
ity from childhood pneumonia. In 
children with HIV, bacterial infection 
remains a major cause of pneumonia 
mortality, but additional pathogens (e.g. 
Pneumocystis jiroveci) are also found in 
HIV-infected children,66,67 while M. 
tuberculosis remains an important cause 
of pneumonia in children with HIV 
and uninfected children.63 Available 
vaccines have lower efficacy in children 
infected with HIV, but still protect 
a significant proportion against dis-
ease.67 Antiretroviral programmes can 
reduce the incidence and severity of 
HIV-associated pneumonia in children 
through the prevention of HIV infec-
tion, use of co-trimoxazole prophylaxis 
and treatment with antiretrovirals.67
Other organisms, such as Myco-
plasma pneumoniae, Chlamydia spp., 
Pseudomonas spp., Escherichia coli, 
and measles, varicella, influenza, his-
toplasmosis and toxoplasmosis, also 
cause pneumonia. Most of them are 
not preventable, but immunization 
against measles, influenza and pos-
sibly use of bacille Calmette–Guérin 
(BCG) have probably contributed 
substantially to decreasing the pneu-
monia burden. There are few data on the 
causes of neonatal pneumonia in devel-
oping countries, but studies of neonatal 
sepsis suggest that these include Gram-
negative enteric organisms, particularly 
Klebsiella spp, and Gram-positive or-
ganisms, mainly pneumococcus, group 
b Streptococcus and S. aureus.68
Box 1.  Risk factors related to the host and the environment that affect incidence of 
childhood clinical pneumonia in the community in developing countries
Definite risk factors
Malnutrition (weight-for-age z-score < –2)
Low birth weight (£ 2500 g)
Non-exclusive breastfeeding (during the first 4 months of life)
Lack of measles immunization (within the first 12 months of life)
Indoor air pollution
Crowding
Likely risk factors
Parental smoking
Zinc deficiency
Mother’s experience as a caregiver
Concomitant diseases (e.g. diarrhoea, heart disease, asthma)
Possible risk factors
Mother’s education
Day-care attendance
Rainfall (humidity)
High altitude (cold air)
Vitamin A deficiency
Birth order
Outdoor air pollution
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Conclusions
About 156 million new episodes of 
childhood clinical pneumonia occurred 
globally in 2000, more than 95% of 
them in developing countries. Of all 
the pneumonia cases occurring in those 
countries, 8.7% are severe enough to 
be life-threatening and require hospital 
admission. About 2 million pneumonia 
deaths occur each year in children aged 
less than 5 years, mainly in the African 
and South-East Asia Regions. The main 
bacterial causes of clinical pneumonia in 
developing countries are S. pneumoniae 
and Hib, and the main viral cause is 
respiratory syncytial virus, but estimates 
of their relative importance vary in dif-
ferent settings. The only vaccines for 
the prevention of bacterial pneumo-
nia (excluding pertussis) are Hib and 
pneumococcal vaccines. Future stud-
ies, with new molecular techniques to 
better detect infections due to the wide 
range of pathogens, will broaden our 
understanding of the cause of pneumo-
nia and may highlight which pathogens 
should be the targets for new vaccines. 
Despite the lack of data, mainly for 
the developing regions of the world, 
morbidity and mortality estimates and 
the main risk factors presented in this 
review could contribute to an under-
standing of the burden of acute lower 
respiratory infections in children aged less 
than 5 years in developing countries and 
to informed care and vaccine policy.  ■
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Résumé
Epidémiologie et étiologie de la pneumonie chez l’enfant
La pneumonie est la principale cause simple de mortalité chez 
les enfants de moins de 5 ans. L’incidence dans cette tranche 
d’âge est estimée à 0,29 épisode/enfant/an dans les pays en 
développement et à 0,05 épisode/enfant/an dans les pays 
développés. Il en résulte environ 156 millions de nouveaux 
épisodes de pneumonie chaque année dans le monde, dont 151 
millions dans les pays en développement. La plupart des cas se 
produisent en Inde (43 millions), en Chine (21 millions), au Pakistan 
(10 millions) et également en grands nombres au Bengladesh, 
en Indonésie et au Nigéria (6 million pour chacun de ces pays). 
Parmi l’ensemble des cas communautaires, 7 à 13 % sont 
assez graves pour menacer le pronostic vital et nécessiter une 
hospitalisation. De nombreux éléments ont fait apparaître comme 
facteurs de risque principaux pour l’incidence de la pneumonie 
l’absence d’allaitement au sein exclusif, la dénutrition, la pollution 
de l’air intérieur, le petit poids à la naissance, le surpeuplement 
et le manque de couverture par la vaccination antirougeoleuse. 
La pneumonie est responsable d’environ 19 % des décès 
d’enfants de moins de 5 ans, dont plus de 70 % se produisent en 
Afrique sub-saharienne et en Asie du Sud-est. Bien que reposant 
sur les données disponibles limitées, les études récentes ont 
identifié Streptococcus pneumonia, Haemophilus influenzae 
et le virus respiratoire syncytial comme les principaux agents 
pathogènes associés à la pneumonie de l’enfant.
Resumen
Epidemiología y etiología de la neumonía en la niñez
La neumonía es la principal causa única de mortalidad entre 
los menores de cinco años. Se estima que la incidencia en ese 
grupo de edad es de 0,29 episodios por niño y año en los países 
en desarrollo y de 0,05 episodios por niño y año en los países 
desarrollados. Ello se traduce en unos 156 millones de episodios 
nuevos cada año en todo el mundo, de los cuales 151 millones 
se registran en el mundo en desarrollo. La mayoría de los casos 
se dan en la India (43 millones), China (21 millones), el Pakistán 
(10 millones), y también presentan cifras altas Bangladesh, 
Indonesia y Nigeria (6 millones cada uno). De todos los 
casos comunitarios, un 7%-13% son lo bastante graves para 
poner en peligro la vida y requerir hospitalización. Numerosos 
datos demuestran que los principales factores de riesgo de 
la incidencia de neumonía son la falta de lactancia materna 
exclusiva, la desnutrición, la contaminación del aire en locales 
cerrados, el bajo peso al nacer, el hacinamiento y la falta 
de inmunización contra el sarampión. La neumonía provoca 
aproximadamente un 19% de todas las defunciones entre los 
niños menores de cinco años, y más del 70% de esas muertes 
se producen en el África subsahariana y en Asia sudoriental. 
Aunque la evidencia disponible es aún limitada, estudios 
recientes señalan a Streptococcus pneumoniae, Haemophilus 
influenzae y el virus sincitial respiratorio como los principales 
agentes patógenos asociados a la neumonía en la niñez.
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صخلم
ليوفطلا يوئرلا باهتللاا تاببسمو تايئابو
 اهدحول يدؤت نأ نكيم يتلا تاببسلما ةعيلط في ليوفطلا يوئرلا باهتللاا ُّدعي
 هذه في ضرلما اذه تاعوقو ر َّدقتو .ةسماخلا نس نود لافطلأا تايفو لىإ
 ةبون 0.05و ،ةيمانلا نادلبلا في ةنس – لفط لكل ةبون  0.29 ـب ةيرمعلا ةئفلا
 ةبون نويلم 156 عوقو ينعي اذهو .ةمدقتلما نادلبلا في ةنس – لفط لكل
 عقتو .يمانلا لماعلا في ًانويلم 151 اهنم ،لماعلا ىوتسم لىع ماع لك ةديدج
 10(  ناتسكابو ،)انويلم 21(  ينصلاو ،)انويلم 43(  دنهلا في تابونلا  مظعم
 اييرجينو ،ايسينودنإو ،شيدلاغنب في اهنم ةيربك ىرخأ دادعأ عوقو عم ،)ينيلام
 عمتجلما في عقت يتلا تابونلا نم %13 – 7 نوكيو .)اهنم لك في ينيلام 6(
 دقو .ىفشتسلما هلاخدإ بلطتيو باصلما لفطلا ةايح ددهي ابم ةماخولا نم
 صقنو  ،  يدثلا  نم  عاضرلإا  لىع  راصتقلاا  مدع  نأ  ةدكؤم  تانيب  ترهظأ
 ماحدزاو ، ةدلاولا دنع نزولا ضافخناو ،لزنلما لخاد ءاوهلا ثولتو ،ةيذغتلا
 ةيسيئرلا راطتخلاا لماوع لثتم هذه لك،ةبصحلا دض عينمتلا صقنو ،نكاسلما
 %19 وحن نع لوؤسم ضرلما اذهو .يوئرلا باهتللااب ةباصلإا في مهست يتلا
 يتلاو،تاونس سمخ نع مهرماعأ لقت نيذلا لافطلأا ينب تايفولا عيمج نم
 بونج نادلبو ،ءارحصلا بونج ةيقيرفلأا نادلبلا في اهنم %70 نم ثركأ عقي
 ةيمدتسلماو ،ةيوئرلا ةيدقعلا نأ لىإ ةثيدحلا تاساردلا تراشأ دقلو .ايسآ قشر
 ةطبترلما ةيسيئرلا ةيضرلما تاببسلما يه ،سيفنتلا يولخلما سويرفلاو ،ةيفزنلا
 اهيلع زكترت يتلا ةرفوتلما تانيبلا ةيدودحم مغر ،ليوفطلا يوئرلا باهتللااب
.تاساردلا هذه
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Appendix A.  Methods and models used to distribute the estimated total annual number of pneumonia episodes by country and WHO 
region7–27
Step Methods and models
Step 1 The Child Health Epidemiology Reference Group (CHERG) working group on pneumonia did an extensive review of the research on 
childhood pneumonia that was subsequently synthesized in a database including more than 2200 sources of information. Further 
details on search strategies, inclusion criteria and methods are published elsewhere.7–9
Step 2 A review of the database with 2200 CHERG studies identified risk factors for pneumonia at the community level. Only studies that 
investigated the role of several risk factors at the same time at the community level using a multivariate design and that included 
more than 500 children were initially used to establish definite, likely and possible risk factors. This step was needed to avoid 
confounding issues and publication bias typical of studies that use univariate design, study a single risk factor or are simply based 
on a too-small sample and lack power.
Step 3 Four studies were identified10–13 and several other methodologically sound studies were used as supporting evidence.14–21
On the basis of those studies, we established three categories of risk factors for development of childhood clinical pneumonia in 
the community. The risk factors were then defined as:
(i) definite (the large majority of evidence consistently pointing to the role of the risk factor):
malnutrition (weight-for-age z-score < –2)
low birth weight (£ 2500 g)
non-exclusive breastfeeding (during the first 4 months of life)
lack of measles immunization within the first 12 months of life
indoor air pollution
crowding
(ii) likely (most evidence consistently pointing to the role, but with some opposing findings; or scarce but consistent evidence of 
the role):
parental smoking
zinc deficiency
mother’s experience as a carer
concomitant diseases (e.g. diarrhoea, heart disease, asthma)
(iii) possible (with sporadic and inconsistent reports of the role in some contexts):
mother’s education
day-care attendance
rainfall (humidity)
high altitude (cold air)
vitamin-A deficiency
birth order
outdoor air pollution.
Step 4 We decided to use only the prevalence of exposure to definite risk factors for distributing global number of pneumonia cases by 
individual countries. However, we decided to exclude measles immunization coverage on two grounds: because the coverage has 
approached high levels in recent years (while the studies that identified it as an important risk factor were done mainly in the 1980s 
and 1990s), so this factor is less discriminative than in was several years ago; and because there is no theoretical justification for 
including it apart from historically serving as a proxy for health system functioning (but this cannot justify its inclusion).
Step 5 After defining five risk factors that will be used to distribute all cases of childhood pneumonia that occur in 1 year globally, this 
total number was computed. It was derived by:
(i) multiplying the number of all children aged less than 5 years living in developing countries (this includes WHO regions AFR D, 
AFR E, AMR B, AMR D, EMR B, EMR D, SEAR B, SEAR D and WPR B)a in the year 2003 with incidence of 0.28 episodes per child-
year, as estimated by Rudan et al.; 8
(ii) multiplying the number of all children aged less than 5 years living in the most developed regions of the world (this includes 
WHO A regions AMR A, EUR A and WPR A) in the year 2003 with incidence of 0.03 episodes per child-year, as estimated by 
Rudan et al.8; the children in EUR B by 0.07 and in EUR C by 0.09;8 and
(iii) adding up all the cases predicted from the first two calculations.
National under-5 population information was obtained from the United Nations Population Division.22
Step 6 Three parameters were then used to distribute the global number of episodes into regional and national estimates:
(i) national under-5 population;22
(ii) prevalence of five of the definite pneumonia risk factors (underweight, low birth weight, non-exclusive breastfeeding during the 
first 4 months of life, indoor air pollution, and crowding); and
(iii) estimates of relative risks for each of these five risk factors.
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Step Methods and models
Step 7 Data on the prevalence of children underweight (weight-for-age z-score < –2), low birth weight (£ 2500 g), and non-exclusive 
breastfeeding (during the first 4 months of life) were obtained from the Demographic and Health Surveys (DHS) or from the 
Multiple Indicators Cluster Surveys (MICS).23–25 Both DHS and MICS are nationally representative household surveys with 
large sample sizes, generally carried out every 3–5 years. Together they cover most developing countries and provide data on 
demographic and health indicators.
Data for the prevalence of indoor air pollution were collected from WHO’s document: Indoor air pollution (national burden of 
disease estimates) 26 as ”percentage of population using solid fuels”.
Data on crowding prevalence (defined as ³ 5 people per household) were obtained from national official governmental information 
retrieved country-by-country from the internet. For the countries where information could not be obtained, national data on the 
prevalence of exposure to specific risk factors were replaced with the mean value calculated for that particular region.
We aimed to collect the information on the prevalence of exposure to these five risk factors for the year 2001–2003.
The table below summarizes the availability of data on the prevalence of risk factors used in this analysis for the year 2003 and 
for developing countries, where more than 95% of pneumonia episodes occur.
Risk factors No. countries with available 
population-based data  
on prevalence of exposure
Prevalence of
exposure
(%)
Estimated number of children 
aged 0–4 years exposed
(million)
Malnutrition (weight-for-age 
z-score < –2)
98 27 141
Low birth weight (£ 2500 g) 107 16 83
Non-exclusive breastfeeding 
(for first 4 months)
98 64 337
Indoor air pollution 117 66 342
Crowding (³ 5 people per 
household)
52 53 278
Step 8 Estimates of relative risks for each of the five definite risk factors for malnutrition, low birth weight, non-exclusive breastfeeding 
and crowding were obtained from available studies10–21 and from Dherani et al. for indoor air pollution (personal communication; 
review is a part of this theme issue). Relative risk was set to the median of relative risks (or odds ratios) reported in these studies. 
We ensured that the definitions of risk factors were the same in the studies estimating relative risk as well as in the surveys that 
measured prevalence of exposure to these risk factors. Relative risks (RR) for the five definite risk factors were applied as follows:
- malnutrition (weight-for-age z-score < –2), RR = 1.8
- low birth weight (£ 2500 g), RR = 1.4
- non-exclusive breastfeeding (during the first 4 months of life), RR = 1.9
- indoor air pollution, RR = 1.8
- crowding, RR = 1.4
Step 9 The global number of new episodes of clinical pneumonia was calculated for each developing country with a model based on the 
epidemiological concept of potential impact fraction27 as follows:
Ne/cy = (Pop < 5yrs) x ( Inc . DevW) x {1 + ( RF = 1 n ) [ (PrevRFn - PrevRFnDevW) x (RRRFn - 1) ] },
where Ne/cy is the number of new clinical pneumonia episodes per year in each developing country, Pop < 5yrs is the population of 
children less than 5 years in each developing country, Inc . DevW is the estimated incidence of clinical pneumonia in the developing 
world, PrevRFn is the prevalence of exposure to n -th risk factor among under-fives in the developing country of interest, PrevRFnDevW 
is the prevalence of exposure to n -th risk factor among under-fives in all developing countries and RRRFn is the relative risk for 
developing clinical pneumonia associated with the n -th risk factor.
Step 10 Cautionary notes on limitations of this approach:
(i) In our calculations, we used the child population estimates for the year 2000 and the prevalence of exposures to risk factors 
relevant to the years 2001–2003; however, the global childhood pneumonia incidence estimate is based mostly on studies 
conducted in the 1980s and 1990s, and so are relative risks associated with different risk factors.
(ii) Prevalence of malnutrition, low birth weight and lack of exclusive breastfeeding mostly comes for MICS and DHS data that 
were made available in 2003–2004, but relevant to the years 2000–2001; indoor air pollution information comes from the 
World Bank’s source and refers to 2002–2003, while the search of the information for crowding was also done during 2002; we 
decided that it is most appropriate to present national-level estimates for the year 2000, as these then ensure consistency and 
complement the papers on global incidence of childhood pneumonia8 and global mortality from childhood pneumonia.7
(iii) Our model, described in step nine, does not necessarily assume that the five risk factors are independent, because we applied 
relative risks derived primarily from the studies of multivariate design; however, it does assume that the magnitude of the five 
chosen risk factors is constant over the whole range of countries, which may not be the case in different environments with 
different combinations of risk factor exposures.
AFR, African Region; AMR, Americas Region; EMR, Eastern Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western Pacific 
Region.
a  WHO regions are subdivided based on child and adult mortality strata: A, very low child and very low adult mortality; B, low child and low adult mortality; C, low child 
and high adult mortality; D, high child and high adult mortality; E, high child and very high adult mortality.
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